Financhill
Sell
42

LLY Quote, Financials, Valuation and Earnings

Last price:
$813.93
Seasonality move :
3.03%
Day range:
$799.00 - $809.12
52-week range:
$637.00 - $972.53
Dividend yield:
0.65%
P/E ratio:
86.93x
P/S ratio:
17.79x
P/B ratio:
53.60x
Volume:
1.8M
Avg. volume:
3.7M
1-year change:
24.66%
Market cap:
$763.3B
Revenue:
$34.1B
EPS (TTM):
$9.25

Analysts' Opinion

  • Consensus Rating
    Eli Lilly and has received a consensus rating of Buy. The company's average rating is a Buy based on 15 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $974.93, Eli Lilly and has an estimated upside of 21.25% from its current price of $804.08.
  • Price Target Downside
    According to analysts, the lowest downside price target is $580.00 representing 27.87% downside risk from its current price of $804.08.

Fair Value

  • According to the consensus of 21 analysts, Eli Lilly and has 21.25% upside to fair value with a price target of $974.93 per share.

LLY vs. S&P 500

  • Over the past 5 trading days, Eli Lilly and has overperformed the S&P 500 by 7.74% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Eli Lilly and does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Eli Lilly and has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Eli Lilly and reported revenues of $11.4B.

Earnings Growth

  • Eli Lilly and has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Eli Lilly and reported earnings per share of $1.07.
Enterprise value:
791B
EV / Invested capital:
--
Price / LTM sales:
17.79x
EV / EBIT:
72.94x
EV / Revenue:
19.36x
PEG ratio (5yr expected):
1.23x
EV / Free cash flow:
-347.65x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
63.21x
Gross Profit (TTM):
$33.1B
Return On Assets:
12.55%
Net Income Margin (TTM):
20.48%
Return On Equity:
66.4%
Return On Invested Capital:
21.5%
Operating Margin:
38.77%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $29.2B $32.1B $40.9B $9.5B $11.4B
Gross Profit $22.1B $25.2B $33.1B $7.6B $9.3B
Operating Income $8.9B $10B $15.1B $3.4B $4.4B
EBITDA $8.5B $8.1B $12.5B $962.8M $2.2B
Diluted EPS $6.57 $5.42 $9.25 -$0.06 $1.07
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $16.2B $17.8B $17.6B $23B $31.4B
Total Assets $43.9B $48.2B $47.5B $57.9B $75.6B
Current Liabilities $12B $13.7B $15.7B $22B $24.7B
Total Liabilities $39B $40.2B $37.3B $46.6B $61.3B
Total Equity $5B $8B $10.2B $11.3B $14.3B
Total Debt $16.9B $17.1B $15.9B $20.2B $31.1B
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations $8.2B $6.2B $6B $2.2B $3.7B
Cash From Investing -$3.3B -$5.2B -$10.3B -$3.1B -$4B
Cash From Financing -$5.8B -$1.2B $5B $572M $211.3M
Free Cash Flow $5.3B -$164.9M -$2.3B -$1.8B -$458.9M
LLY
Sector
Market Cap
$763.3B
$44.8M
Price % of 52-Week High
82.68%
47.62%
Dividend Yield
0.65%
0%
Shareholder Yield
0.32%
-0.79%
1-Year Price Total Return
24.66%
-33.29%
Beta (5-Year)
0.413
0.745
Dividend yield:
0.65%
Annualized payout:
$4.52
Payout ratio:
54.13%
Growth streak:
9 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $773.91
200-day SMA
Sell
Level $838.92
Bollinger Bands (100)
Sell
Level 768.44 - 898.8
Chaikin Money Flow
Buy
Level 1.2B
20-day SMA
Buy
Level $773.47
Relative Strength Index (RSI14)
Buy
Level 57.49
ADX Line
Buy
Level 19.55
Williams %R
Sell
Level -13.2434
50-day SMA
Buy
Level $778.42
MACD (12, 26)
Buy
Level 1.44
25-day Aroon Oscillator
Buy
Level 24
On Balance Volume
Neutral
Level 1.3B

Financial Scores

Buy
Altman Z-Score (Annual)
Level (7.0115)
Sell
CA Score (Annual)
Level (-1.099)
Sell
Beneish M-Score (Annual)
Level (-2.1804)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (0.6899)
Buy
Piotroski F Score (Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (9)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Stock Forecast FAQ

In the current month, LLY has received 15 Buy ratings 6 Hold ratings, and 0 Sell ratings. The LLY average analyst price target in the past 3 months is $974.93.

  • Where Will Eli Lilly and Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Eli Lilly and share price will rise to $974.93 per share over the next 12 months.

  • What Do Analysts Say About Eli Lilly and?

    Analysts are divided on their view about Eli Lilly and share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Eli Lilly and is a Sell and believe this share price will drop from its current level to $580.00.

  • What Is Eli Lilly and's Price Target?

    The price target for Eli Lilly and over the next 1-year time period is forecast to be $974.93 according to 21 Wall Street analysts, 15 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.

  • Is LLY A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Eli Lilly and is a Buy. 15 of 21 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of LLY?

    You can purchase shares of Eli Lilly and via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Eli Lilly and shares.

  • What Is The Eli Lilly and Share Price Today?

    Eli Lilly and was last trading at $813.93 per share. This represents the most recent stock quote for Eli Lilly and. Yesterday, Eli Lilly and closed at $804.08 per share.

  • How To Buy Eli Lilly and Stock Online?

    In order to purchase Eli Lilly and stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is AST SpaceMobile Stock Dropping?
Why Is AST SpaceMobile Stock Dropping?

Since Donald Trump’s pledge to send American astronauts to Mars…

1 Space Stock Up Over 150%, More To Go?
1 Space Stock Up Over 150%, More To Go?

Planet Labs combines satellite imaging and data analytics technologies to…

How High Will Rubrik Stock Go?
How High Will Rubrik Stock Go?

Shares of cybersecurity company Rubrik (NYSE:RBRK) have been on a…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 39x

Buy
57
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
42
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 104x

Alerts

Sell
32
MANH alert for Jan 30

Manhattan Associates [MANH] is down 3.29% over the past day.

Buy
66
HZO alert for Jan 30

MarineMax [HZO] is up 6.17% over the past day.

Buy
89
EAT alert for Jan 30

Brinker International [EAT] is up 1.52% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock